soliris
alexion europe sas - ekulizumab - hemoglobinurie, paroxysmální - imunosupresiva - přípravek soliris je indikován u dospělých a dětí k léčbě:paroxysmální noční hemoglobinurie (pnh). důkazy o klinické prospěšnosti je prokázána u pacientů s hemolýza s klinickým příznakem(s) svědčí o vysoké aktivity nemoci, bez ohledu na to, transfúze historie (viz bod 5. atypický hemolyticko-uremický syndrom (ahus). přípravek soliris je indikován u dospělých k léčbě:Žáruvzdorné generalizované myasthenia gravis (gmg) u pacientů, kteří jsou anti-acetylcholinové receptory (achr) protilátky-pozitivní (viz bod 5. neuromyelitis optica spectrum disorder (nmosd) u pacientů, kteří jsou anti-aquaporin-4 (aqp4) protilátky-pozitivní s recidivující průběh onemocnění.
ultomiris
alexion europe sas - ravulizumab - hemoglobinurie, paroxysmální - selektivní imunosupresiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
clozapine aristo 100mg tableta
aristo pharma gmbh, berlin array - 1739 klozapin - tableta - 100mg - klozapin
clozapine aristo 25mg tableta
aristo pharma gmbh, berlin array - 1739 klozapin - tableta - 25mg - klozapin
tiapra 100mg potahovaná tableta
zentiva, k.s., praha array - 5538 tiaprid-hydrochlorid - potahovaná tableta - 100mg - tiaprid
clozapin desitin 100mg tableta
desitin arzneimittel gmbh, hamburg array - 1739 klozapin - tableta - 100mg - klozapin
clozapin desitin 25mg tableta
desitin arzneimittel gmbh, hamburg array - 1739 klozapin - tableta - 25mg - klozapin
leponex 100mg tableta
viatris healthcare limited, dublin array - 1739 klozapin - tableta - 100mg - klozapin
leponex 25mg tableta
viatris healthcare limited, dublin array - 1739 klozapin - tableta - 25mg - klozapin
sulpiride grindeks 100mg tableta
as grindeks, riga lotyŠsko - 4417 sulpirid - tableta - 100mg - sulpirid